Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB

Claus Roehrborn, Steven A. Kaplan, Stephen R. Kraus, Joseph T. Wang, Tamara Bavendam, Zhonghong Guan

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives: To evaluate the efficacy of tolterodine extended release (ER), tamsulosin, and tolterodine ER plus tamsulosin in men with symptoms of overactive bladder and benign prostatic hyperplasia stratified by prostate-specific antigen (PSA) level. Methods: We performed a post hoc analysis of data from men ≥40 years old with frequency and urgency (with or without urge urinary incontinence), postvoid residual urine volume <200 mL, maximal urinary flow rate >5 mL/s, International Prostate Symptom Score (IPSS) of ≥12, and quality-of-life score of ≥3. They had been randomized to placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER plus tamsulosin for 12 weeks. The men were stratified by the median baseline PSA level (≥1.3 vs <1.3 ng/mL). Assessments included changes in bladder diary variables and IPSSs. The men rated the urgency level of each micturition, and the frequency-urgency sum was defined as the total of these ratings. Results: The PSA level correlated significantly with prostate size. Men with a PSA level of ≥1.3 ng/mL receiving tolterodine ER plus tamsulosin showed significantly greater improvements in 24-hour frequency, daytime frequency, the frequency-urgency sum, total IPSS, and IPSS storage score compared with those receiving placebo. Tamsulosin significantly improved the IPSS voiding scores, but tolterodine ER was ineffective. In men with a PSA level <1.3 ng/mL, tolterodine ER alone and tolterodine ER plus tamsulosin significantly improved the 24-hour frequency, daytime frequency, frequency-urgency sum, and IPSS storage scores compared with those receiving placebo; tamsulosin alone was ineffective. No significant changes were found in the postvoid residual urine volume or maximal urinary flow rate in any group, and the acute urinary retention rates were low. Conclusions: The results of our study have shown that tolterodine ER was efficacious in men with lower urinary tract symptoms, including overactive bladder, who had lower PSA levels (<1.3 ng/mL).

Original languageEnglish (US)
Pages (from-to)1061-1067
Number of pages7
JournalUrology
Volume72
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

tamsulosin
Prostate-Specific Antigen
Prostate
Serum
Overactive Urinary Bladder
Residual Volume
Placebos
Urine
Urge Urinary Incontinence
Tolterodine Tartrate
Lower Urinary Tract Symptoms
Urinary Retention
Urination
Prostatic Hyperplasia

ASJC Scopus subject areas

  • Urology

Cite this

Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB. / Roehrborn, Claus; Kaplan, Steven A.; Kraus, Stephen R.; Wang, Joseph T.; Bavendam, Tamara; Guan, Zhonghong.

In: Urology, Vol. 72, No. 5, 11.2008, p. 1061-1067.

Research output: Contribution to journalArticle

Roehrborn, Claus ; Kaplan, Steven A. ; Kraus, Stephen R. ; Wang, Joseph T. ; Bavendam, Tamara ; Guan, Zhonghong. / Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB. In: Urology. 2008 ; Vol. 72, No. 5. pp. 1061-1067.
@article{13985cc96a4344b198c163739dd73660,
title = "Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB",
abstract = "Objectives: To evaluate the efficacy of tolterodine extended release (ER), tamsulosin, and tolterodine ER plus tamsulosin in men with symptoms of overactive bladder and benign prostatic hyperplasia stratified by prostate-specific antigen (PSA) level. Methods: We performed a post hoc analysis of data from men ≥40 years old with frequency and urgency (with or without urge urinary incontinence), postvoid residual urine volume <200 mL, maximal urinary flow rate >5 mL/s, International Prostate Symptom Score (IPSS) of ≥12, and quality-of-life score of ≥3. They had been randomized to placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER plus tamsulosin for 12 weeks. The men were stratified by the median baseline PSA level (≥1.3 vs <1.3 ng/mL). Assessments included changes in bladder diary variables and IPSSs. The men rated the urgency level of each micturition, and the frequency-urgency sum was defined as the total of these ratings. Results: The PSA level correlated significantly with prostate size. Men with a PSA level of ≥1.3 ng/mL receiving tolterodine ER plus tamsulosin showed significantly greater improvements in 24-hour frequency, daytime frequency, the frequency-urgency sum, total IPSS, and IPSS storage score compared with those receiving placebo. Tamsulosin significantly improved the IPSS voiding scores, but tolterodine ER was ineffective. In men with a PSA level <1.3 ng/mL, tolterodine ER alone and tolterodine ER plus tamsulosin significantly improved the 24-hour frequency, daytime frequency, frequency-urgency sum, and IPSS storage scores compared with those receiving placebo; tamsulosin alone was ineffective. No significant changes were found in the postvoid residual urine volume or maximal urinary flow rate in any group, and the acute urinary retention rates were low. Conclusions: The results of our study have shown that tolterodine ER was efficacious in men with lower urinary tract symptoms, including overactive bladder, who had lower PSA levels (<1.3 ng/mL).",
author = "Claus Roehrborn and Kaplan, {Steven A.} and Kraus, {Stephen R.} and Wang, {Joseph T.} and Tamara Bavendam and Zhonghong Guan",
year = "2008",
month = "11",
doi = "10.1016/j.urology.2008.06.067",
language = "English (US)",
volume = "72",
pages = "1061--1067",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB

AU - Roehrborn, Claus

AU - Kaplan, Steven A.

AU - Kraus, Stephen R.

AU - Wang, Joseph T.

AU - Bavendam, Tamara

AU - Guan, Zhonghong

PY - 2008/11

Y1 - 2008/11

N2 - Objectives: To evaluate the efficacy of tolterodine extended release (ER), tamsulosin, and tolterodine ER plus tamsulosin in men with symptoms of overactive bladder and benign prostatic hyperplasia stratified by prostate-specific antigen (PSA) level. Methods: We performed a post hoc analysis of data from men ≥40 years old with frequency and urgency (with or without urge urinary incontinence), postvoid residual urine volume <200 mL, maximal urinary flow rate >5 mL/s, International Prostate Symptom Score (IPSS) of ≥12, and quality-of-life score of ≥3. They had been randomized to placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER plus tamsulosin for 12 weeks. The men were stratified by the median baseline PSA level (≥1.3 vs <1.3 ng/mL). Assessments included changes in bladder diary variables and IPSSs. The men rated the urgency level of each micturition, and the frequency-urgency sum was defined as the total of these ratings. Results: The PSA level correlated significantly with prostate size. Men with a PSA level of ≥1.3 ng/mL receiving tolterodine ER plus tamsulosin showed significantly greater improvements in 24-hour frequency, daytime frequency, the frequency-urgency sum, total IPSS, and IPSS storage score compared with those receiving placebo. Tamsulosin significantly improved the IPSS voiding scores, but tolterodine ER was ineffective. In men with a PSA level <1.3 ng/mL, tolterodine ER alone and tolterodine ER plus tamsulosin significantly improved the 24-hour frequency, daytime frequency, frequency-urgency sum, and IPSS storage scores compared with those receiving placebo; tamsulosin alone was ineffective. No significant changes were found in the postvoid residual urine volume or maximal urinary flow rate in any group, and the acute urinary retention rates were low. Conclusions: The results of our study have shown that tolterodine ER was efficacious in men with lower urinary tract symptoms, including overactive bladder, who had lower PSA levels (<1.3 ng/mL).

AB - Objectives: To evaluate the efficacy of tolterodine extended release (ER), tamsulosin, and tolterodine ER plus tamsulosin in men with symptoms of overactive bladder and benign prostatic hyperplasia stratified by prostate-specific antigen (PSA) level. Methods: We performed a post hoc analysis of data from men ≥40 years old with frequency and urgency (with or without urge urinary incontinence), postvoid residual urine volume <200 mL, maximal urinary flow rate >5 mL/s, International Prostate Symptom Score (IPSS) of ≥12, and quality-of-life score of ≥3. They had been randomized to placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER plus tamsulosin for 12 weeks. The men were stratified by the median baseline PSA level (≥1.3 vs <1.3 ng/mL). Assessments included changes in bladder diary variables and IPSSs. The men rated the urgency level of each micturition, and the frequency-urgency sum was defined as the total of these ratings. Results: The PSA level correlated significantly with prostate size. Men with a PSA level of ≥1.3 ng/mL receiving tolterodine ER plus tamsulosin showed significantly greater improvements in 24-hour frequency, daytime frequency, the frequency-urgency sum, total IPSS, and IPSS storage score compared with those receiving placebo. Tamsulosin significantly improved the IPSS voiding scores, but tolterodine ER was ineffective. In men with a PSA level <1.3 ng/mL, tolterodine ER alone and tolterodine ER plus tamsulosin significantly improved the 24-hour frequency, daytime frequency, frequency-urgency sum, and IPSS storage scores compared with those receiving placebo; tamsulosin alone was ineffective. No significant changes were found in the postvoid residual urine volume or maximal urinary flow rate in any group, and the acute urinary retention rates were low. Conclusions: The results of our study have shown that tolterodine ER was efficacious in men with lower urinary tract symptoms, including overactive bladder, who had lower PSA levels (<1.3 ng/mL).

UR - http://www.scopus.com/inward/record.url?scp=54449099907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449099907&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2008.06.067

DO - 10.1016/j.urology.2008.06.067

M3 - Article

C2 - 18817961

AN - SCOPUS:54449099907

VL - 72

SP - 1061

EP - 1067

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -